|
Vaccine Detail
Seasonal Influenza Vaccine -- Advax |
Vaccine Information |
- Vaccine Name: Seasonal Influenza Vaccine -- Advax
- Target Pathogen: Influenza virus
- Target Disease: Influenza (flu)
- Type: trivalent human seasonal influenza vaccine (TIV)
- Status: Clinical trial
- Host Species for Licensed Use: Mouse
- Antigen: TIV (CSL): H1N1, H3N2, B; also inactivated PR8
- Adjuvant:
- Preparation: "Virus stocks were propagated in the allantoic fluid of 10- to 11-day-old fertile chicken eggs and purified by sucrose gradient ultracentrifugation as previously described [11] and stored at −80 °C until use. Advax™ adjuvant was combined with influenza antigen by simple admixture prior to immunization" (Honda-Okubo et al., 2012)
- Immunization Route: Intramuscular injection (i.m.)
|
Host Response |
Mouse Response
- Immune Response: Advax™ adjuvant increased neutralizing antibody and memory B-cell responses to influenza. It similarly enhanced CD4 and "CD8 T-cell proliferation and increased influenza-stimulated IL-2, IFN-γ, IL-5, IL-6, and GM-CSF responses. This translated into enhanced protection against mortality and morbidity in mice"
|
References |
Honda-Okubo et al., 2012: Honda-Okubo Y, Saade F, Petrovsky N. Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine. 2012; 30(36); 5373-5381. [PubMed: 22728225].
|
|